Basit öğe kaydını göster

dc.contributor.authorSÜT, NECDET
dc.contributor.authorGül, Ahmet
dc.contributor.authorDinc, Ayhan
dc.contributor.authorSimsek, Ismail
dc.contributor.authorYazici, Hasan
dc.contributor.authorMat, Cem
dc.contributor.authorCosan, Fulya
dc.contributor.authorKilic, Hasan
dc.contributor.authorZeytin, Hasan E.
dc.contributor.authorKORKMAZ, Cengiz
dc.date.accessioned2021-03-05T14:47:58Z
dc.date.available2021-03-05T14:47:58Z
dc.date.issued2009
dc.identifier.citationKilic H., Zeytin H. E. , KORKMAZ C., Mat C., Gül A., Cosan F., Dinc A., Simsek I., SÜT N., Yazici H., "Low-dose natural human interferon-alpha lozenges in the treatment of Behcet's syndrome", RHEUMATOLOGY, cilt.48, ss.1388-1391, 2009
dc.identifier.issn1462-0324
dc.identifier.otherav_b8e3b7ae-459c-4b64-98f6-23f3d4feb24a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/123025
dc.identifier.urihttps://doi.org/10.1093/rheumatology/kep237
dc.description.abstractObjectives. There had been evidence that low-dose local IFN could be beneficial in the management of recurrent oral ulcers (OUs). We investigated the efficacy and collected initial data on the safety of low-dose natural human IFN-alpha administered by the oral mucosal route in Behcet's syndrome (BS) in a placebo controlled, double blind study.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.titleLow-dose natural human interferon-alpha lozenges in the treatment of Behcet's syndrome
dc.typeMakale
dc.relation.journalRHEUMATOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume48
dc.identifier.issue11
dc.identifier.startpage1388
dc.identifier.endpage1391
dc.contributor.firstauthorID194037


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster